Shinpoong Pharmaceutical Co.,Ltd (KRX:019170)
South Korea
· Delayed Price · Currency is KRW 7,570.00
+20.00 (0.26%)
Apr 18, 2025, 3:30 PM KST
KRX:019170 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 221,094 | 200,229 | 209,288 | 189,237 | 197,751 | Upgrade
|
| Other Revenue | - | - | -0 | - | - | Upgrade
|
| Revenue | 221,094 | 200,229 | 209,288 | 189,237 | 197,751 | Upgrade
|
| Revenue Growth (YoY) | 10.42% | -4.33% | 10.60% | -4.30% | 4.23% | Upgrade
|
| Cost of Revenue | 139,290 | 119,951 | 131,315 | 111,850 | 121,224 | Upgrade
|
| Gross Profit | 81,804 | 80,277 | 77,973 | 77,388 | 76,527 | Upgrade
|
| Selling, General & Admin | 77,764 | 79,068 | 76,549 | 69,256 | 59,480 | Upgrade
|
| Research & Development | 17,879 | 42,277 | 30,383 | 17,334 | 5,622 | Upgrade
|
| Other Operating Expenses | 800.65 | 394.37 | 646.98 | 3,241 | 778.8 | Upgrade
|
| Operating Expenses | 98,833 | 127,670 | 111,992 | 91,694 | 68,782 | Upgrade
|
| Operating Income | -17,029 | -47,392 | -34,019 | -14,306 | 7,746 | Upgrade
|
| Interest Expense | -2,632 | -1,719 | -61.42 | -202.06 | -2,945 | Upgrade
|
| Interest & Investment Income | 704.06 | 1,174 | 1,026 | 1,878 | 1,946 | Upgrade
|
| Earnings From Equity Investments | - | -6,514 | -697.09 | 2,620 | 2,520 | Upgrade
|
| Currency Exchange Gain (Loss) | 2,833 | 1,328 | -1,009 | 406.81 | -1,128 | Upgrade
|
| Other Non Operating Income (Expenses) | 279.23 | 653.36 | -182.48 | 314.91 | -415.97 | Upgrade
|
| EBT Excluding Unusual Items | -15,844 | -52,471 | -34,942 | -9,288 | 7,724 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1,215 | -1,011 | 845.62 | 253.64 | -868.38 | Upgrade
|
| Gain (Loss) on Sale of Assets | 6.89 | 39.65 | 18.31 | 49.02 | -29.96 | Upgrade
|
| Asset Writedown | - | - | -703.23 | - | - | Upgrade
|
| Pretax Income | -14,622 | -53,442 | -34,782 | -8,986 | 8,340 | Upgrade
|
| Income Tax Expense | 751.41 | 3,831 | 527.29 | 2,540 | 3,294 | Upgrade
|
| Earnings From Continuing Operations | -15,373 | -57,273 | -35,309 | -11,526 | 5,046 | Upgrade
|
| Minority Interest in Earnings | -13.8 | -52.86 | -68.14 | -57.61 | -42.93 | Upgrade
|
| Net Income | -15,387 | -57,325 | -35,377 | -11,584 | 5,003 | Upgrade
|
| Net Income to Common | -15,387 | -57,325 | -35,377 | -11,584 | 5,003 | Upgrade
|
| Net Income Growth | - | - | - | - | -6.03% | Upgrade
|
| Shares Outstanding (Basic) | 51 | 51 | 51 | 51 | 50 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 51 | 51 | 51 | 50 | Upgrade
|
| Shares Change (YoY) | - | - | - | 1.85% | 0.71% | Upgrade
|
| EPS (Basic) | -300.17 | -1118.28 | -690.12 | -225.97 | 99.40 | Upgrade
|
| EPS (Diluted) | -300.17 | -1118.28 | -690.12 | -225.97 | 99.40 | Upgrade
|
| EPS Growth | - | - | - | - | -2.22% | Upgrade
|
| Free Cash Flow | -20,724 | -39,696 | -31,767 | -75,453 | 17,408 | Upgrade
|
| Free Cash Flow Per Share | -404.27 | -774.37 | -619.69 | -1471.90 | 345.89 | Upgrade
|
| Dividend Per Share | - | - | - | - | 100.000 | Upgrade
|
| Gross Margin | 37.00% | 40.09% | 37.26% | 40.89% | 38.70% | Upgrade
|
| Operating Margin | -7.70% | -23.67% | -16.25% | -7.56% | 3.92% | Upgrade
|
| Profit Margin | -6.96% | -28.63% | -16.90% | -6.12% | 2.53% | Upgrade
|
| Free Cash Flow Margin | -9.37% | -19.82% | -15.18% | -39.87% | 8.80% | Upgrade
|
| EBITDA | -5,066 | -35,484 | -21,215 | -1,631 | 19,954 | Upgrade
|
| EBITDA Margin | -2.29% | -17.72% | -10.14% | -0.86% | 10.09% | Upgrade
|
| D&A For EBITDA | 11,963 | 11,908 | 12,803 | 12,675 | 12,208 | Upgrade
|
| EBIT | -17,029 | -47,392 | -34,019 | -14,306 | 7,746 | Upgrade
|
| EBIT Margin | -7.70% | -23.67% | -16.25% | -7.56% | 3.92% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 39.50% | Upgrade
|
| Advertising Expenses | 16,981 | 17,979 | 19,126 | 17,097 | 15,574 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.